A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT01578707 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

391

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: ofatumumab
DRUG: ibrutinib

Sponsor

Pharmacyclics LLC.

Collaborators

[object Object]